Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic

Kolenová, Alexandra; Bubanská, Eva; Oravkinova, Irina; Z, Subova; Mikesková, Martina; Hederová, Stanislava; Petrzalkova, Dana; Striezencova, Zuzana Laluhova; Fabri, Oksana; Copáková, Lucia; Chocholová, Alica; Sufliarska, Sabina; Horáková, Júlia; Čáp, Ján; Foltinová, A; Sejnová, Daniela; Kaiserová, E

doi:10.1007/s12254-012-0052-x

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each year in the Slovak Republic, which has about 1.1 million children, approximately 40 pediatric leukemia cases are diagnosed, including 30 cases of acute lymphoblastic leukemia, 6-8 cases of acute myeloid leukemia, and 1-2 cases of chronic myeloid leukemia [16,23,24]. Children with leukemia are treated in 3 centers, which are well distributed across Slovakia.…”

Section: Discussionmentioning

confidence: 99%

Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic

Kolenová¹,

Kaiserová²,

Makohusová³

et al. 2015

neo

View full text Add to dashboard Cite

Our aim was to analyze event-free (EFS) and overall survival (OS) among children and adolescents with acute lymphoblastic leukemia (ALL) treated with International BFM Intercontinental trial (ALL IC 2002) therapy in the Slovak Republic. In total, 280 children and adolescent age 1 to 18 years were treated with ALL IC BFM 2002 based therapy from 2002 to 2012, which was divided into two periods. During 2002During -2007, when patients were actively enrolled in the ALL IC-BFM 2002 trial, and during 2008-2012 when the trial was closed and patients were treated with the same therapy without randomization. Five-year EFS and OS rates were 79% (+/-2.6%) and 86% (+/-2.1%), respectively, similar to results obtained in the ALL-BFM 95 trial, which was the basis for ALL IC BFM 2002 therapy. The EFS (p<0.012) and OS (p<0.003) were significantly better than the prior Slovak experience in [1997][1998][1999][2000][2001]. Survival is improved in standard and intermediate risk groups, including those age 1 to 6 years, and older; with B-cell or T-cell immunophenotype, and is also excellent for those with good early response. The rate of death in induction, cumulative incidence of death in complete remission and of relapse decreased. However, outcome was suboptimal for patients in the high risk group. Current EFS and OS rates for children and adolescents with ALL in the Slovak Republic resembled those obtained in Western Europe as a result of clinical trial participation, and clinical experience acquired with intensive BFM type treatment. Key words: acute lymphoblastic leukemia, children, clinical trialThe treatment of childhood acute lymphoblastic leukemia (ALL) is one of the success stories of clinical oncology [1,2,3]. Pediatric ALL 5-year overal survival (OS) rates have improved to approximately 90% in trials conducted in North America and Western Europe with risk stratification by biological features of leukaemic cells and response to treatment and improved supportive care [4,5,6,7,8,9,10]. The outstanding outcome has been obtained in countries with highly developed health care systems and has been possible because of high enrollment in clinical trials by cooperative groups and large institutions, with the two largest being the Children's Oncology Group (COG) based in North America and the [12]. Children with ALL in Slovakia were included in the ALL IC-BFM 2002 trial, which was designed for countries inside the I-BFM study group who had achieved event-free survival (EFS) rates of at least 65%, but were not able to utilize the minimal residual disease (MRD) testing employed in recent BFM trials [11,12]. The ALL IC BFM 2002 prospective randomized international trial provided the first experience for Slovakia to participate in an international pediatric ALL treatment study. Prior to 1992, Slovakian children diagnosed with ALL and other malignancies were treated in several different children's departments using a variety of therapies. Starting in 1992, pediatric cancer therapy in Slovakia was centralized in three children's oncolo...

show abstract

Section: Discussionmentioning

confidence: 99%

Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic

Kolenová¹,

Kaiserová²,

Makohusová³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…In this issue of memo, reports from groups in Poland [14], Czech Republic [15], Hungary [16], Slovakia [17], and Serbia [18] will further introduce the history of the treatment of childhood AML in each country during the last 10-30 years. They show that new diagnostic methods have been introduced and that patients were classified into risk groups.…”

Section: Treatment Of Childhood Aml In Middle and Eastern Europementioning

confidence: 99%

Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries

Creutzig

Tallen

2013

memo

View full text Add to dashboard Cite

“…Recently, a valuable overview over the past and current standards, treatment results as well as challenges in the management of pediatric AML throughout several European countries including Czech Republic, Hungary, Serbia, Slovak Republic, and Poland was provided in Memo [1][2][3][4][5][6]. In this issue, further three European national pediatric hemato-oncology study groups (from Austria, Greece, and Slovenia) report their data-which were collected over a long observation period of 20 years-in a similar way [7][8][9].…”

mentioning

confidence: 99%

Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

Dworzak

2014

memo

View full text Add to dashboard Cite

Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic

Cited by 3 publications

References 13 publications

Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic

Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic

Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries

Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

Contact Info

Product

Resources

About